Novartis’s Pelacarsen Trial Failure Challenges the Lp(a) Drug Thesis
Pelacarsen’s failed cardiovascular outcomes trial raises questions for Novartis, Lp(a)-targeting therapies and cardiology drug pipelines.
Pfizer’s Monthly GLP-1 Strategy Could Challenge Lilly and Novo Nordisk
Pfizer’s reported 12% weight-loss result and monthly dosing strategy could reshape expectations for the obesity-drug market.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
Corvus Rally Puts Cash Runway and Soquelitinib Milestones in the Spotlight
CRVS rose 8.53% after its Q3 call, putting cash runway and upcoming soquelitinib milestones at the center of the biotech…
CAPR Traders Position for FDA Decision as Hiring Clues Fuel Retail Speculation
CAPR rose more than 4% overnight as retail traders debated whether hiring listings signal launch preparations ahead of a…
Moderna’s Dual US-Canada Vaccine Wins Put Respiratory Portfolio in Focus
Moderna’s US and Canadian vaccine authorizations sharpen the case for a broader respiratory franchise beyond COVID-19 pr…
Gilead Shares a New Livdelzi Catalyst as Phase 3 PBC Data Move Toward Regulatory Talks
Positive Phase 3 IDEAL data for Livdelzi could give Gilead a regulatory catalyst and strengthen its non-HIV pipeline div…
Palatin Technologies Regains Buy Rating as Analysts Highlight Melanocortin Pipeline
H.C. Wainwright resumed coverage of Palatin with a buy rating, highlighting Vyleesi, MC4R expertise and prior business-d…
Edgewise Therapeutics Shares Jump on Takeover Interest Report: What Traders Should Watch
EWTX gained after a report of takeover interest, putting deal-premium speculation and catalyst-driven volatility at the …
Satellos Resets DMD Trial Endpoint After FDA Talks as Investors Weigh the Data
Satellos Bioscience changed its DMD trial endpoint after FDA discussions, while open-label MRI data showed a 3.7-point r…
Moonlake’s FDA Alignment Sets Up a Key BLA Catalyst for MLTX Investors
Moonlake reports no remaining FDA gaps, putting an expected November 29 BLA acceptance date at the center of the MLTX re…
J&J’s Rybrevant Approval Adds a New Oncology Catalyst for Investors
Johnson & Johnson’s accelerated FDA approval for Rybrevant strengthens its oncology pipeline and puts regulatory executi…